GrippeBelgiqueV4, Main, Exploration, bibRecord, 000059

Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.

Identifieur interne : 000059 ( Main/Exploration ); précédent : 000058; suivant : 000060

Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.

Auteurs : Nilufer E. Broeders [Belgique] ; Anneleen Hombrouck ; Anne Lemy ; Karl Martin Wissing ; Judith Racapé ; Karine Gastaldello ; Annick Massart ; Steven Van Gucht ; Laura Weichselbaum ; Aurelie De Mul ; Bernard Brochier ; Isabelle Thomas ; Daniel Abramowicz

Source :

Clinical journal of the American Society of Nephrology : CJASN [ 1555-905X ] ; 2011.

RBID : pubmed:21921153

Descripteurs français

KwdFr :
- Adulte, Adulte d'âge moyen, Analyse de régression, Analyse de variance, Anticorps antiviraux (sang), Anticorps neutralisants (sang), Antigènes d'histocompatibilité de classe I (immunologie), Antigènes d'histocompatibilité de classe II (immunologie), Association médicamenteuse, Belgique, Dialyse rénale, Défaillance rénale chronique (), Défaillance rénale chronique (immunologie), Facteurs temps, Femelle, Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (virologie), Humains, Immunosuppresseurs (administration et posologie), Loi du khi-deux, Mâle, Odds ratio, Polysorbates (administration et posologie), Résultat thérapeutique, Sous-type H1N1 du virus de la grippe A (immunologie), Squalène (administration et posologie), Sujet âgé, Transplantation rénale, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), alpha-Tocophérol (administration et posologie), Études cas-témoins, Études de cohortes.
MESH :
- administration et posologie : Immunosuppresseurs, Polysorbates, Squalène, Vaccins antigrippaux, alpha-Tocophérol.
- effets indésirables : Vaccins antigrippaux.
- immunologie : Antigènes d'histocompatibilité de classe I, Antigènes d'histocompatibilité de classe II, Défaillance rénale chronique, Grippe humaine, Sous-type H1N1 du virus de la grippe A.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- virologie : Grippe humaine.
- Adulte, Adulte d'âge moyen, Analyse de régression, Analyse de variance, Association médicamenteuse, Belgique, Dialyse rénale, Défaillance rénale chronique, Facteurs temps, Femelle, Grippe humaine, Humains, Loi du khi-deux, Mâle, Odds ratio, Résultat thérapeutique, Sujet âgé, Transplantation rénale, Études cas-témoins, Études de cohortes.
Wicri :
- geographic : Belgique.

English descriptors

KwdEn :
- Adult, Aged, Analysis of Variance, Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Belgium, Case-Control Studies, Chi-Square Distribution, Cohort Studies, Drug Combinations, Female, Histocompatibility Antigens Class I (immunology), Histocompatibility Antigens Class II (immunology), Humans, Immunosuppressive Agents (administration & dosage), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Kidney Failure, Chronic (immunology), Kidney Failure, Chronic (surgery), Kidney Failure, Chronic (therapy), Kidney Transplantation, Male, Middle Aged, Odds Ratio, Polysorbates (administration & dosage), Regression Analysis, Renal Dialysis, Squalene (administration & dosage), Time Factors, Treatment Outcome, alpha-Tocopherol (administration & dosage).
MESH :
- chemical , administration & dosage : Immunosuppressive Agents, Influenza Vaccines, Polysorbates, Squalene, alpha-Tocopherol.
- chemical , adverse effects : Influenza Vaccines.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , immunology : Histocompatibility Antigens Class I, Histocompatibility Antigens Class II.
- geographic : Belgium, Drug Combinations.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza, Human, Kidney Failure, Chronic.
- prevention & control : Influenza, Human.
- surgery : Kidney Failure, Chronic.
- therapy : Kidney Failure, Chronic.
- virology : Influenza, Human.
- Adult, Aged, Analysis of Variance, Case-Control Studies, Chi-Square Distribution, Cohort Studies, Female, Humans, Kidney Transplantation, Male, Middle Aged, Odds Ratio, Regression Analysis, Renal Dialysis, Time Factors, Treatment Outcome.

Abstract

BACKGROUND AND OBJECTIVES

In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There are few data concerning the immunogenicity or the security of the adjuvanted-A/H1N1 vaccine in transplanted and hemodialyzed patients.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS

Sera from 21 controls, 53 hemodialyzed (HD) patients, and 111 renal transplant recipients (RT) were sampled before (T0) and 1 month after (T1) a single dose of Pandemrix® vaccine (GSK Biologicals, AS03-adjuvanted). We measured the neutralizing antibodies against A/H1N1/2009, the geometric mean (GM) titers, the GM titer ratios (T1/T0) with 95% confidence intervals, and the seroconversion rate (responders: ≥4-fold increase in titer). The HLA and MICA immunization was determined by Luminex technology.

RESULTS

The GM titer ratio was 38 (19 to 78), 9 (5 to 16), and 5 (3 to 6) for controls, HD patients, and RT patients, respectively (P < 0.001). The proportion of responders was 90%, 57%, and 44%, respectively (P < 0.001). In RT patients, the prevalence of histocompatibility leukocyte antigen (HLA) class I, histocompatibility leukocyte antigen class II, and MHC class I-related chain A immunization, was, respectively, 15%, 14%, and 14% before and 14%, 14%, and 11% after vaccination (P = 1, 1, and 0.39).

CONCLUSIONS

The influenza A/H1N1-adjuvanted vaccine is of limited efficacy but is safe in renal disease populations. The humoral response is lower in transplanted versus hemodialyzed patients. Further studies are needed to improve the efficacy of vaccination in those populations.

DOI: 10.2215/CJN.04670511
PubMed: 21921153

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000064
to stream Main, to step Curation: 000064

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.</title>
<author><name sortKey="Broeders, Nilufer E" sort="Broeders, Nilufer E" uniqKey="Broeders N" first="Nilufer E" last="Broeders">Nilufer E. Broeders</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Clinic, Hospital Erasme, Brussels, Belgium. broedersnilufer@gmail.com</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Renal Transplantation Clinic, Hospital Erasme, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hombrouck, Anneleen" sort="Hombrouck, Anneleen" uniqKey="Hombrouck A" first="Anneleen" last="Hombrouck">Anneleen Hombrouck</name>
</author>
<author><name sortKey="Lemy, Anne" sort="Lemy, Anne" uniqKey="Lemy A" first="Anne" last="Lemy">Anne Lemy</name>
</author>
<author><name sortKey="Wissing, Karl Martin" sort="Wissing, Karl Martin" uniqKey="Wissing K" first="Karl Martin" last="Wissing">Karl Martin Wissing</name>
</author>
<author><name sortKey="Racape, Judith" sort="Racape, Judith" uniqKey="Racape J" first="Judith" last="Racapé">Judith Racapé</name>
</author>
<author><name sortKey="Gastaldello, Karine" sort="Gastaldello, Karine" uniqKey="Gastaldello K" first="Karine" last="Gastaldello">Karine Gastaldello</name>
</author>
<author><name sortKey="Massart, Annick" sort="Massart, Annick" uniqKey="Massart A" first="Annick" last="Massart">Annick Massart</name>
</author>
<author><name sortKey="Van Gucht, Steven" sort="Van Gucht, Steven" uniqKey="Van Gucht S" first="Steven" last="Van Gucht">Steven Van Gucht</name>
</author>
<author><name sortKey="Weichselbaum, Laura" sort="Weichselbaum, Laura" uniqKey="Weichselbaum L" first="Laura" last="Weichselbaum">Laura Weichselbaum</name>
</author>
<author><name sortKey="De Mul, Aurelie" sort="De Mul, Aurelie" uniqKey="De Mul A" first="Aurelie" last="De Mul">Aurelie De Mul</name>
</author>
<author><name sortKey="Brochier, Bernard" sort="Brochier, Bernard" uniqKey="Brochier B" first="Bernard" last="Brochier">Bernard Brochier</name>
</author>
<author><name sortKey="Thomas, Isabelle" sort="Thomas, Isabelle" uniqKey="Thomas I" first="Isabelle" last="Thomas">Isabelle Thomas</name>
</author>
<author><name sortKey="Abramowicz, Daniel" sort="Abramowicz, Daniel" uniqKey="Abramowicz D" first="Daniel" last="Abramowicz">Daniel Abramowicz</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21921153</idno>
<idno type="pmid">21921153</idno>
<idno type="doi">10.2215/CJN.04670511</idno>
<idno type="wicri:Area/Main/Corpus">000064</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000064</idno>
<idno type="wicri:Area/Main/Curation">000064</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000064</idno>
<idno type="wicri:Area/Main/Exploration">000064</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.</title>
<author><name sortKey="Broeders, Nilufer E" sort="Broeders, Nilufer E" uniqKey="Broeders N" first="Nilufer E" last="Broeders">Nilufer E. Broeders</name>
<affiliation wicri:level="3"><nlm:affiliation>Renal Transplantation Clinic, Hospital Erasme, Brussels, Belgium. broedersnilufer@gmail.com</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Renal Transplantation Clinic, Hospital Erasme, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hombrouck, Anneleen" sort="Hombrouck, Anneleen" uniqKey="Hombrouck A" first="Anneleen" last="Hombrouck">Anneleen Hombrouck</name>
</author>
<author><name sortKey="Lemy, Anne" sort="Lemy, Anne" uniqKey="Lemy A" first="Anne" last="Lemy">Anne Lemy</name>
</author>
<author><name sortKey="Wissing, Karl Martin" sort="Wissing, Karl Martin" uniqKey="Wissing K" first="Karl Martin" last="Wissing">Karl Martin Wissing</name>
</author>
<author><name sortKey="Racape, Judith" sort="Racape, Judith" uniqKey="Racape J" first="Judith" last="Racapé">Judith Racapé</name>
</author>
<author><name sortKey="Gastaldello, Karine" sort="Gastaldello, Karine" uniqKey="Gastaldello K" first="Karine" last="Gastaldello">Karine Gastaldello</name>
</author>
<author><name sortKey="Massart, Annick" sort="Massart, Annick" uniqKey="Massart A" first="Annick" last="Massart">Annick Massart</name>
</author>
<author><name sortKey="Van Gucht, Steven" sort="Van Gucht, Steven" uniqKey="Van Gucht S" first="Steven" last="Van Gucht">Steven Van Gucht</name>
</author>
<author><name sortKey="Weichselbaum, Laura" sort="Weichselbaum, Laura" uniqKey="Weichselbaum L" first="Laura" last="Weichselbaum">Laura Weichselbaum</name>
</author>
<author><name sortKey="De Mul, Aurelie" sort="De Mul, Aurelie" uniqKey="De Mul A" first="Aurelie" last="De Mul">Aurelie De Mul</name>
</author>
<author><name sortKey="Brochier, Bernard" sort="Brochier, Bernard" uniqKey="Brochier B" first="Bernard" last="Brochier">Bernard Brochier</name>
</author>
<author><name sortKey="Thomas, Isabelle" sort="Thomas, Isabelle" uniqKey="Thomas I" first="Isabelle" last="Thomas">Isabelle Thomas</name>
</author>
<author><name sortKey="Abramowicz, Daniel" sort="Abramowicz, Daniel" uniqKey="Abramowicz D" first="Daniel" last="Abramowicz">Daniel Abramowicz</name>
</author>
</analytic>
<series><title level="j">Clinical journal of the American Society of Nephrology : CJASN</title>
<idno type="eISSN">1555-905X</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Antibodies, Neutralizing (blood)</term>
<term>Antibodies, Viral (blood)</term>
<term>Belgium</term>
<term>Case-Control Studies</term>
<term>Chi-Square Distribution</term>
<term>Cohort Studies</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Histocompatibility Antigens Class I (immunology)</term>
<term>Histocompatibility Antigens Class II (immunology)</term>
<term>Humans</term>
<term>Immunosuppressive Agents (administration & dosage)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Kidney Failure, Chronic (immunology)</term>
<term>Kidney Failure, Chronic (surgery)</term>
<term>Kidney Failure, Chronic (therapy)</term>
<term>Kidney Transplantation</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Odds Ratio</term>
<term>Polysorbates (administration & dosage)</term>
<term>Regression Analysis</term>
<term>Renal Dialysis</term>
<term>Squalene (administration & dosage)</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
<term>alpha-Tocopherol (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de régression</term>
<term>Analyse de variance</term>
<term>Anticorps antiviraux (sang)</term>
<term>Anticorps neutralisants (sang)</term>
<term>Antigènes d'histocompatibilité de classe I (immunologie)</term>
<term>Antigènes d'histocompatibilité de classe II (immunologie)</term>
<term>Association médicamenteuse</term>
<term>Belgique</term>
<term>Dialyse rénale</term>
<term>Défaillance rénale chronique ()</term>
<term>Défaillance rénale chronique (immunologie)</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Immunosuppresseurs (administration et posologie)</term>
<term>Loi du khi-deux</term>
<term>Mâle</term>
<term>Odds ratio</term>
<term>Polysorbates (administration et posologie)</term>
<term>Résultat thérapeutique</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Squalène (administration et posologie)</term>
<term>Sujet âgé</term>
<term>Transplantation rénale</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>alpha-Tocophérol (administration et posologie)</term>
<term>Études cas-témoins</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Immunosuppressive Agents</term>
<term>Influenza Vaccines</term>
<term>Polysorbates</term>
<term>Squalene</term>
<term>alpha-Tocopherol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Histocompatibility Antigens Class I</term>
<term>Histocompatibility Antigens Class II</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Belgium</term>
<term>Drug Combinations</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Immunosuppresseurs</term>
<term>Polysorbates</term>
<term>Squalène</term>
<term>Vaccins antigrippaux</term>
<term>alpha-Tocophérol</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes d'histocompatibilité de classe I</term>
<term>Antigènes d'histocompatibilité de classe II</term>
<term>Défaillance rénale chronique</term>
<term>Grippe humaine</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza, Human</term>
<term>Kidney Failure, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Kidney Failure, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Kidney Failure, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Case-Control Studies</term>
<term>Chi-Square Distribution</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Kidney Transplantation</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Odds Ratio</term>
<term>Regression Analysis</term>
<term>Renal Dialysis</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de régression</term>
<term>Analyse de variance</term>
<term>Association médicamenteuse</term>
<term>Belgique</term>
<term>Dialyse rénale</term>
<term>Défaillance rénale chronique</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Loi du khi-deux</term>
<term>Mâle</term>
<term>Odds ratio</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Transplantation rénale</term>
<term>Études cas-témoins</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Belgique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND AND OBJECTIVES</b>
</p>
<p>In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There are few data concerning the immunogenicity or the security of the adjuvanted-A/H1N1 vaccine in transplanted and hemodialyzed patients.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS</b>
</p>
<p>Sera from 21 controls, 53 hemodialyzed (HD) patients, and 111 renal transplant recipients (RT) were sampled before (T0) and 1 month after (T1) a single dose of Pandemrix® vaccine (GSK Biologicals, AS03-adjuvanted). We measured the neutralizing antibodies against A/H1N1/2009, the geometric mean (GM) titers, the GM titer ratios (T1/T0) with 95% confidence intervals, and the seroconversion rate (responders: ≥4-fold increase in titer). The HLA and MICA immunization was determined by Luminex technology.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>The GM titer ratio was 38 (19 to 78), 9 (5 to 16), and 5 (3 to 6) for controls, HD patients, and RT patients, respectively (P < 0.001). The proportion of responders was 90%, 57%, and 44%, respectively (P < 0.001). In RT patients, the prevalence of histocompatibility leukocyte antigen (HLA) class I, histocompatibility leukocyte antigen class II, and MHC class I-related chain A immunization, was, respectively, 15%, 14%, and 14% before and 14%, 14%, and 11% after vaccination (P = 1, 1, and 0.39).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>The influenza A/H1N1-adjuvanted vaccine is of limited efficacy but is safe in renal disease populations. The humoral response is lower in transplanted versus hemodialyzed patients. Further studies are needed to improve the efficacy of vaccination in those populations.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21921153</PMID>
<DateCompleted><Year>2012</Year>
<Month>02</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-905X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>6</Volume>
<Issue>11</Issue>
<PubDate><Year>2011</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Clinical journal of the American Society of Nephrology : CJASN</Title>
<ISOAbbreviation>Clin J Am Soc Nephrol</ISOAbbreviation>
</Journal>
<ArticleTitle>Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.</ArticleTitle>
<Pagination><MedlinePgn>2573-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2215/CJN.04670511</ELocationID>
<Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There are few data concerning the immunogenicity or the security of the adjuvanted-A/H1N1 vaccine in transplanted and hemodialyzed patients.</AbstractText>
<AbstractText Label="DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS" NlmCategory="METHODS">Sera from 21 controls, 53 hemodialyzed (HD) patients, and 111 renal transplant recipients (RT) were sampled before (T0) and 1 month after (T1) a single dose of Pandemrix® vaccine (GSK Biologicals, AS03-adjuvanted). We measured the neutralizing antibodies against A/H1N1/2009, the geometric mean (GM) titers, the GM titer ratios (T1/T0) with 95% confidence intervals, and the seroconversion rate (responders: ≥4-fold increase in titer). The HLA and MICA immunization was determined by Luminex technology.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The GM titer ratio was 38 (19 to 78), 9 (5 to 16), and 5 (3 to 6) for controls, HD patients, and RT patients, respectively (P < 0.001). The proportion of responders was 90%, 57%, and 44%, respectively (P < 0.001). In RT patients, the prevalence of histocompatibility leukocyte antigen (HLA) class I, histocompatibility leukocyte antigen class II, and MHC class I-related chain A immunization, was, respectively, 15%, 14%, and 14% before and 14%, 14%, and 11% after vaccination (P = 1, 1, and 0.39).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The influenza A/H1N1-adjuvanted vaccine is of limited efficacy but is safe in renal disease populations. The humoral response is lower in transplanted versus hemodialyzed patients. Further studies are needed to improve the efficacy of vaccination in those populations.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Broeders</LastName>
<ForeName>Nilufer E</ForeName>
<Initials>NE</Initials>
<AffiliationInfo><Affiliation>Renal Transplantation Clinic, Hospital Erasme, Brussels, Belgium. broedersnilufer@gmail.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hombrouck</LastName>
<ForeName>Anneleen</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lemy</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wissing</LastName>
<ForeName>Karl Martin</ForeName>
<Initials>KM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Racapé</LastName>
<ForeName>Judith</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gastaldello</LastName>
<ForeName>Karine</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Massart</LastName>
<ForeName>Annick</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Van Gucht</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Weichselbaum</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>De Mul</LastName>
<ForeName>Aurelie</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brochier</LastName>
<ForeName>Bernard</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Thomas</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Abramowicz</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>09</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin J Am Soc Nephrol</MedlineTA>
<NlmUniqueID>101271570</NlmUniqueID>
<ISSNLinking>1555-9041</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C550253">ASO3B adjuvant</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099187">MHC class I-related chain A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C556153">pandemrix</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7QWM220FJH</RegistryNumber>
<NameOfSubstance UI="D013185">Squalene</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>H4N855PNZ1</RegistryNumber>
<NameOfSubstance UI="D024502">alpha-Tocopherol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000949" MajorTopicYN="N">Histocompatibility Antigens Class II</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024502" MajorTopicYN="N">alpha-Tocopherol</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>9</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>9</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>3</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21921153</ArticleId>
<ArticleId IdType="pii">CJN.04670511</ArticleId>
<ArticleId IdType="doi">10.2215/CJN.04670511</ArticleId>
<ArticleId IdType="pmc">PMC3359578</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vaccine. 2011 Mar 16;29(13):2461-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21256188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2010 Jul 27;90(2):168-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20463636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 2011 May;57(5):716-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21349617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2011 Jun 15;203(12):1729-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21606531</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nephrol Dial Transplant. 2011 Jun;26(6):2018-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20974645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nephrol Dial Transplant. 2012 Jan;27(1):423-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21613386</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2000 Feb 15;69(3):436-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10706057</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2004 Nov;4 Suppl 10:160-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15504229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann N Y Acad Sci. 1995 May 31;754:329-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7625669</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 1996 Feb;22(2):295-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8838186</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nephrol Dial Transplant. 1998 Jan;13(1):160-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9481733</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 1999 Apr;37(4):937-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10074505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Microbiol. 1958 Dec;19(3):540-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13611196</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2005 Sep;5(9):2265-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16095508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Nephrol. 2006;26(2):206-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16699258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2007 Feb;7(2):408-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17229080</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2007 Sep 27;357(13):1293-300</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17898098</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2008 Jan;8(1):9-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18093271</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2008 Feb;8(2):332-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18162092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2009 May 27;87(10):1505-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19461487</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 2009 Jul;54(1):112-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19185404</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Kidney Dis. 2009 Jul;54(1):77-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19339089</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2009 Aug 27;88(4):568-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19696641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Aug 28;58(33):913-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19713879</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Recomm Rep. 2009 Aug 28;58(RR-10):1-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19713882</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2009 Oct;9(10):2346-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19656126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2424-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745215</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Dec 17;361(25):2405-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745216</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Transplant. 2010 Jan;10(1):18-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19958321</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 2010 Apr 15;89(7):838-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20179666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Transplant. 2010 Jan-Feb;24(1):E17-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19758368</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nephrol Dial Transplant. 2011 Apr;26(4):1424-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21273236</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Belgique</li>
</country>
<region><li>Région de Bruxelles-Capitale</li>
</region>
<settlement><li>Bruxelles</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Abramowicz, Daniel" sort="Abramowicz, Daniel" uniqKey="Abramowicz D" first="Daniel" last="Abramowicz">Daniel Abramowicz</name>
<name sortKey="Brochier, Bernard" sort="Brochier, Bernard" uniqKey="Brochier B" first="Bernard" last="Brochier">Bernard Brochier</name>
<name sortKey="De Mul, Aurelie" sort="De Mul, Aurelie" uniqKey="De Mul A" first="Aurelie" last="De Mul">Aurelie De Mul</name>
<name sortKey="Gastaldello, Karine" sort="Gastaldello, Karine" uniqKey="Gastaldello K" first="Karine" last="Gastaldello">Karine Gastaldello</name>
<name sortKey="Hombrouck, Anneleen" sort="Hombrouck, Anneleen" uniqKey="Hombrouck A" first="Anneleen" last="Hombrouck">Anneleen Hombrouck</name>
<name sortKey="Lemy, Anne" sort="Lemy, Anne" uniqKey="Lemy A" first="Anne" last="Lemy">Anne Lemy</name>
<name sortKey="Massart, Annick" sort="Massart, Annick" uniqKey="Massart A" first="Annick" last="Massart">Annick Massart</name>
<name sortKey="Racape, Judith" sort="Racape, Judith" uniqKey="Racape J" first="Judith" last="Racapé">Judith Racapé</name>
<name sortKey="Thomas, Isabelle" sort="Thomas, Isabelle" uniqKey="Thomas I" first="Isabelle" last="Thomas">Isabelle Thomas</name>
<name sortKey="Van Gucht, Steven" sort="Van Gucht, Steven" uniqKey="Van Gucht S" first="Steven" last="Van Gucht">Steven Van Gucht</name>
<name sortKey="Weichselbaum, Laura" sort="Weichselbaum, Laura" uniqKey="Weichselbaum L" first="Laura" last="Weichselbaum">Laura Weichselbaum</name>
<name sortKey="Wissing, Karl Martin" sort="Wissing, Karl Martin" uniqKey="Wissing K" first="Karl Martin" last="Wissing">Karl Martin Wissing</name>
</noCountry>
<country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Broeders, Nilufer E" sort="Broeders, Nilufer E" uniqKey="Broeders N" first="Nilufer E" last="Broeders">Nilufer E. Broeders</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeBelgiqueV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000059 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000059 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeBelgiqueV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:21921153
   |texte=   Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21921153" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeBelgiqueV4

This area was generated with Dilib version V0.6.35.
Data generation: Mon Jul 6 21:52:38 2020. Site generation: Sat Sep 26 09:27:55 2020

	Corpus GrippeBelgiqueV4
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeBelgiqueV4

Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.

Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki